角膜手术全球市场-2022-2029

市场概览

2021 年角膜手术市场价值为 4.155 亿美元。预计在预测期内（2022-2029 年）将以 6.20% 的复合年增长率增长。

角膜手术是一种移植手术，用捐赠者的角膜组织替换部分角膜。它涉及用器官捐献者的健康组织替换患病或受损的角膜组织。角膜手术可以帮助恢復视力、减轻疼痛并改善受损或患病角膜的外观。有几个因素会损害角膜，包括真菌性角膜炎、倒睫、Fuchs 角膜炎、圆锥角膜等感染、眼外伤和角膜烧伤。

角膜手术可有效缓解与角膜疾病相关的体征和症状。角膜手术可以治疗多种疾病，包括圆锥角膜、Fuchs角膜变性、角膜变薄、角膜瘢痕、角膜混浊、角膜肿胀和角膜溃疡。

市场动态

由于视障人士的增加促进市场增长

随着越来越多的人患有视力障碍，对角膜手术的需求也在增加。根据世界卫生组织 (WHO) 的数据，全世界约有 2.17 亿人患有中度至重度视力障碍。此外，约有 3700 万人失明。在全球范围内，50 岁以上的人中有 82% 是盲人。根据 Surgical Eye Expeditions International 的数据，角膜是世界上导致失明的主要原因。全球约有 5.1% 的人口，即 1200 万人因角膜问题而失明。角膜是视力丧失的主要原因，仅次于白内障、青光眼和年龄相关性黄斑变性。每年，全世界有超过 350,000 名儿童在出生时患有或在幼年时患上导致角膜失明的感染。

对角膜手术设备开发的资金和投资不断增加，预计将在预测期内推动市场增长。

一些组织、协会和基金会正在加大对角膜手术设备开发的投资和资助。例如，2020 年 8 月，澳大利亚眼科研究中心和墨尔本大学的角膜研究人员宣布了一种名为 Corel 的手术设备，这是一种超薄水凝胶薄膜，可以插入供体角膜组织以恢復患者眼睛的视力。获得维多利亚医学研究加速基金 (VMRAF) 的 500,000 美元赠款，用于加速这笔资金将用于 18 个月的临床前工作，以与大学和美国眼库 EverSight 合作改进和测试 CorGel。

与角膜手术相关的不良事件阻碍市场增长

与角膜手术相关的一些不良事件正在阻碍市场增长。不良事件包括感染、出血、疼痛、发红、对光敏感和眼压升高。角膜手术会增加患眼部感染、晶状体混浊、供体角膜排斥和角膜肿胀的风险。在十分之一的角膜移植中，身体的免疫系统会攻击捐赠的组织。角膜排斥反应的发生率为 20%。接受角膜移植的患者也可能发生移植失败。

COVID-19 影响分析

全球角膜手术市场受到 COVID-19 流行病的影响。这是因为随着 COVID-19 患者人数的增加，接受角膜手术的患者人数正在减少。 COVID-19 可能对角膜手术的实施构成重大威胁。 COVID-19 大流行源于自愿捐赠者数量与角膜手术之间的供需失衡。由于一些眼科医生已经停止了所有非紧急和急救治疗，因此接受角膜手术的人越来越少。此外，由于 COVID-19 大流行，每个国家的眼科医院和眼库都被禁止将死者的眼球带回家。根据卡纳塔克邦眼科学会的数据，由于缺乏供体眼球或 Covid 阴性检测报告，角膜移植的数量下降了 90% 以上。许多患者无法进行角膜手术，因为他们没有足够的角膜进行角膜手术。根据 Parekh、Mohit 等人在 2020 年发表在《欧洲眼科学杂誌》上的数据，全球约有 270 万患者正在等待角膜移植。威尼托眼库见证了来自国内外 250 名外科医生网络的供体角膜减少了 95%。

流行病学

眼科角膜病是全球失明的主要原因。角膜眼病影响全球超过 1000 万人。几种疾病是全球角膜失明的主要原因，包括角膜混浊、沙眼、角膜瘢痕、角膜营养不良和角膜新生血管。根据世界卫生组织 (WHO) 的数据，大约有 1.46 亿人患有沙眼。大约有 1000 万人患有倒睫，需要通过手术来预防角膜失明。大约 490 万人因沙眼导致的角膜瘢痕而失明。

根据全球视力数据库，角膜混浊影响全球约 3*21% 的人口。角膜混浊占东亚人口的4*26%，中亚人口的3.58%，南亚人口的2.43%，中欧人口的3.63%，东欧人口的3.43% ，和西欧3.43%的人口。据说影响2.43%。在美国，角膜营养不良的总体患病率为每 100,000 人中有 897 人。大约 60% 的角膜营养不良是内皮的。

市场细分

在角膜手术市场中，深前板层角膜移植术细分市场有望占据很大份额

按移植类型，角膜手术市场分为深前板层角膜移植术、穿透性角膜移植术和合成角膜。深前板层角膜移植术是角膜手术治疗市场的最大部分，因为越来越多地采用深前板层角膜移植术来治疗圆锥角膜、角膜外翻、角膜基质营养不良和角膜瘢痕形成。预计将占据份额。深前板层角膜移植术是一种将角膜基质去除至后弹力膜的外科手术。选择性移植角膜基质的部分厚度角膜移植，留下原始的后弹力膜和内皮。它是对角膜前表面所有病变的有效治疗，包括上皮、鲍曼层和基质。前段深部角膜移植术的使用表明，这种手术程序可以保留患者之间的宿主内皮，从而降低排斥率。接受深前板层角膜移植术的患者也经历了更短的癒合时间、更少的术后并发症和更少的局部类固醇。

根据手术类型，预计穿透性角膜移植术在预测期内将显着增长

市场按手术类型分为术前检查、渗透性角膜移植术和板层角膜移植术。渗透性角膜移植术占据了很大的市场份额，因为它是全世界最常进行的手术。根据辛辛那提眼科研究所 (CEI) 的数据，美国每年进行大约 45,000 例渗透性角膜移植手术。穿透性角膜移植术包括通过手术切除中央三分之二的受损角膜并插入匹配的清晰、健康的供体组织。用于角膜水肿、角膜溃疡、角膜营养不良、Fuch氏营养不良、圆锥角膜等病症的治疗和管理。研究表明，角膜移植可使患者存活 10 年或更长时间。

区域分析

北美在全球角膜手术市场中占有最大的市场份额。

北美地区主导着全球角膜手术市场，并将在 2021 年占据最大的市场份额。随着盲人数量的增加，越来越多的人接受角膜手术，预计美国将在该地区占据最大份额。根据美国疾病控制与预防中心 (CDC) 的数据，美国有 100 万人失明，约 1200 万人有视力障碍。根据美国眼科学会的数据，2013 年美国进行了大约 48,229 例角膜移植手术。自 1961 年以来，美国已有超过 100 万名年龄在 9 天至 100 岁及以上的男性、女性和儿童通过角膜手术恢復了视力。

开发角膜手术设备的市场参与者数量正在增加。几家公司已投资并筹集资金用于角膜手术设备的开发。先进的角膜手术方法的使用正在增加。有几个组织、协会和基金会可以提高对角膜手术的认识。例如，美国角膜研究基金会 (CRFA) 是一家致力于角膜疾病、角膜移植和人工晶状体手术的非营利性临床研究和教育组织。此外，几家公司正在推出外科视觉中心。例如，2019 年 7 月，强生公司在佛罗里达州杰克逊维尔的强生研究所启动了外科视觉体验中心。该中心是 Johnson & Johnson Vision 首屈一指的体育训练空间和实验室，可用于各种体验式教育计划，为执业眼科医生、眼科住院医师和验光师提供动手、深入的培训。它将发挥作用。更好的医疗设施和基础设施的可用性预计将刺激市场增长。

预计亚太地区在预测期内将以最快的复合年增长率增长

亚太地区是全球角膜估计是手术市场增长最快的地区。根据全球眼库协会联盟 (GAEBA) 的数据，亚洲约有 280 万人受到角膜失明的影响。由于角膜疾病，大约 680 万人的至少一隻眼睛的视力丧失为 6/60 或更少。其中，100 万人患有双侧疾病。根据国家防治失明计划（NPCB），2013 年印度有 120,000 人患有角膜失明。每年有 25,000 至 30,000 例新的角膜失明病例。此外，印度于 1976 年启动了国家失明和视力障碍控制计划，中央政府提供 100% 的资金，到 2020 年将失明率降至 0.3%。在 2016-17 年度，该计划收集了用于角膜移植的捐赠眼睛，在 50,000 隻的目标中实现了 65,135 只。

由于眼科诊所、医院和其他进行角膜手术的医疗机构的增加，预计印度、中国、日本和澳大利亚等国家的市场将出现大幅增长。人们对捐眼重要性的认识日益提高，预计也将对市场产生积极影响。几家公司专注于开发技术先进的角膜手术器械。政府正在加紧努力在诊所和医院提供低成本的眼科手术。眼保健设施、眼库框架和角膜交易协议的改进预计将增加对角膜手术的需求。

竞合情势。

角膜手术市场是一个分散的市场，市场参与者众多。 Nidek Co. Ltd.、Johnson & Johnson、Essilor International S.A.、Topcon Corporation、Ziemer Ophthalmic Systems AG、Carl Zeiss Meditec、Bausch &Lomb、Abbott Medical、Alcon Laboratories、Meditec AG、Medical Optics Inc 和 Cooper Vision 拥有较大的市场份额主要参与者。主要参与者采用了多种增长战略，例如产品发布、产品批准、合併、许可、收购和合作伙伴关係，为全球角膜手术市场的增长做出了贡献。例如：

合併与合作。

2019 年 10 月，TECLens 与 SERVimed Industrial Spa 合作开发和 FDA 批准治疗圆锥角膜的新组合产品。正在开发的新产品结合了 TECLens 的 CXLens“眼上”交联繫统，用于角膜重塑和 SERVImed 的跨上皮 RIBOCROSS 核黄素配方。

2022 年 7 月 18 日，Carl Zeiss Meditech 与 Plessis Bio 合作，开始开发和商业化用于眼科的加工角膜组织。根据该协议，Carl Zeiss Meditech 将投资 Precise Bio 开发角膜移植产品。

产品发布和批准

2021 年 5 月 24 日，Haag-Streit UK 在英国推出了眼科分析仪“Eyestar 900”。扫频技术可以精确测量整个眼球，并对角膜的前后表面以及包括晶状体的前房进行地形评估。除了对所有这些结构进行成像外，它还包括从角膜到视网膜的整个眼睛的生物特征。

2019 年 7 月 31 日，强生视力宣布在佛罗里达州杰克逊维尔的强生研究所开设外科视力体验中心。外科中心作为其首要的体育训练空间和实验室环境，提供各种体验式教育计划，为执业眼科医生、眼科住院医师和验光师提供动手、深入的培训。

收购

2021 年 7 月 14 日，拓普康公司宣布已收购眼科设备製造商 VISIA Imaging S.r.l.。此次收购将加强拓普康在眼前节设备和软件方面的开发和製造能力。分段设备包括相机和光学相干断层扫描 (OCT)。

内容

第1章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

• 按设备类型划分的市场细分
• 按移植类型划分的市场细分
• 按程序划分的市场细分
• 最终用户的市场细分
• 按地区划分的市场细分

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • 视力障碍患病率上升
    • 技术进步
  • 限制
    • 使用角膜手术器械引起的不良事件
  • 商机
  • 影响分析

第5章行业分析

• 波特五力分析
• 流行病学
• 管道分析
• 供应链分析
• 定价分析
• 法律法规分析
• 保险报销分析
• 未满足的需求分析

第 6 章 COVID-19 分析

• COVID-19 的市场分析
  • COVID-19 之前的市场情景
  • COVID-19 的当前市场情景
  • COVID-19 后或未来情景
• COVID-19 期间的价格动态
• 供需范围
• 大流行期间与市场相关的政府举措
• 製造商的战略举措
• 总结

第 7 章按设备类型

• 诊断设备
  • 眼底相机
  • 角膜曲率计
  • 角膜地形图师
  • 眼科超声诊断成像系统
  • 其他
• 角膜手术设备
• 视力保健

第 8 章按移植类型

• 前板层角膜深层移植
• 通孔角膜移植
• 人工角膜
  • 波士顿人工角膜
  • alpha 调用
  • Osteo Odonto 人工角膜
• 其他

第 9 章技术

• 术前检查
• 通孔角膜移植
• 板层角膜移植术

第 10 章，最终用户

• 眼科诊所
• 医院
• 其他

第 11 章按地区划分

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 12 章竞争格局

• 竞争场景
• 市场情况/份额分析
• 併购分析

第 13 章公司简介

• 尼迪克有限公司
  • 公司概况
  • 产品组合和描述
  • 主要亮点
  • 财务摘要
• Johnson & Johnson
• Essilor International S.A.
• Topcon Corporation
• Ziemer Ophthalmic Systems AG
• Haag-Streit
• Carl Zeiss Meditec
• Bausch & Lomb
• Abbott Medical
• KeraMED
• Alcon Laboratories
• Meditec AG
• Medical Optics Inc.
• Cooper Vision（LIST NOT EXHAUSTIVE）

第14章 DataM

Market Overview

Corneal Surgery Market was valued at USD 415.5 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 6.20% during the forecast period (2022-2029).

Corneal surgery is the procedure for the transplantation of the cornea for replacing the part of the cornea with corneal tissue from a donor. It involves the replacement of the diseased or scarred corneal tissue with healthy tissue from an organ donor. Corneal surgery is useful to restore vision, reduce pain and improve the appearance of a damaged or diseased cornea. Several factors such as infections including fungal keratitis, trichiasis, Fuchs' dystrophy, and keratoconus, eye injury, cornea burns, and other factors can damage the Cornea.

Corneal surgery is effective to relieve signs and symptoms associated with cornea diseases. Corneal surgery can treat various conditions such as keratoconus, Fuchs' dystrophy, cornea thinning, cornea scarring, cornea clouding, cornea swelling, corneal ulcers, and others.

Market Dynamics

Rising Prevalence of Visual Impairment is Driving the Growth of the Market

The demand for corneal surgery is increasing with the increasing number of people affected by vision impairment. According to the World Health Organization (WHO), approximately 217 million people have moderate to severe vision impairment worldwide. Around 37 million people are blind. Globally, 82% of people in the age-group 50 years and above are blind. According to Surgical Eye Expeditions International, Cornea is the leading cause of blindness globally. Around 5.1% of the global population, i.e., 12 million people, are blind due to cornea. The cornea is the major cause of visual deficiency after cataracts, glaucoma, and age-related macular degeneration. Every year, more than 350,000 children are born with or develop infections at a young age that cause corneal blindness across the globe.

Increasing funding & investment for the development of corneal surgery devices is expected to boost the market growth over the forecast period

Several organizations, associations, and foundations are raising the investment and funding for the development of corneal surgery devices. For instance, in August 2020, The Centre for Eye Research Australia's corneal researchers and the University of Melbourne received a grant of USD 500,000 from the Victorian Medical Research Acceleration Fund (VMRAF) to accelerate the development of a surgical device known as 'Corel,' an ultra-thin hydrogel film that is inserted into the donor corneal tissue into a patient's eye to restore vision. This funding would be used to support the 18 months of preclinical work to refine and test CorGel in collaboration with the University and US eye bank EverSight.

Adverse events associated with corneal surgery are hampering the Market Growth

Several adverse events associated with corneal surgery are hindering market growth. Adverse events such as infection, bleeding, pain, redness, sensitivity to light, higher pressure in the eye, and others. Corneal surgery increases the risk of developing an eye infection, clouding of the eye's lens, rejection of the donor cornea, and cornea swelling. In corneal transplants, the body's immune system attacks the donated tissue in one out of every 10 transplants. Cornea rejection can occur in 20% of the cases. Graft failure can also occur among the patients transplanted with the cornea.

COVID-19 Impact Analysis

The global corneal surgery market has been impacted due to the COVID-19 pandemic, as there has been a reduction in the number of patients undergoing corneal surgery with the increasing number of people suffering from COVID-19. COVID-19 can be a serious threat to carrying out corneal surgery. The COVID-19 pandemic has resulted from the imbalance between the supply-demand between the number of voluntary donors and corneal surgery. There is a decrease in the number of people undergoing corneal surgery as several ophthalmologists have ceased providing any treatment other than urgent or emergent care. Moreover, eye hospitals and eye banks are prohibited from taking home retrieval of eyes from dead individuals in various countries owing to the emergence of the COVID-19 pandemic. According to the Karnataka Ophthalmic Society, the number of corneal transplants has decreased by more than 90% as either people are not coming forward to donate the eyes of the dead people or there is no Covid-negative test report. Several patients have been waiting to undergo corneal surgery as there are shortages of corneas for performing the surgery. According to Parekh, Mohit et al. 2020, published in the European Journal of Ophthalmology, around 2.7 million patients are waiting for corneal transplants worldwide. Veneto Eye Bank has witnessed a 95% reduction in donor corneas from its network of 250 local and international surgeons.

Epidemiology

Corneal eye diseases are the major cause of blindness worldwide. Corneal eye diseases affect more than 10 million people worldwide. Several conditions, such as corneal opacity, trachoma, corneal scarring, corneal dystrophies, and corneal vascularization, are the leading cause of corneal blindness across the globe. According to the World Health Organization, around 146 million people are suffering from trachoma. Around 10 million are affected by trichiasis and need surgery to prevent corneal blindness. Approximately 4.9 million are blind due to trachomatous corneal scarring.

According to the Global Vision Database, corneal opacity affects around 3*21% of the population across the globe. Corneal opacity affects 4*26% of the population in East Asia, 3.58% of the population in Central Asia, 2.43% of the population in South Asia, 3.63% of the population in Central Europe, 3.43% of the population in Eastern Europe, and 2.43% of the population in Western Europe. The overall prevalence of corneal dystrophies was 897 per 1000,000 in the United States. Around 60% of all corneal dystrophies are endothelial.

Market Segment Analysis

The Deep Anterior Lamellar Keratoplasty segment is expected to hold a significant share in the Corneal Surgery market

By transplantation type, the corneal surgery market is segmented as deep anterior lamellar keratoplasty, penetrating keratoplasty, and synthetic corneas. The deep anterior lamellar keratoplasty segment is anticipated to hold the largest share in the corneal surgery treatment market owing to the increasing adoption of the deep anterior lamellar keratoplasty for the treatment of keratoconus, corneal ectasia, corneal stromal dystrophies, and corneal scars. Deep anterior lamellar keratoplasty is the surgical procedure for removing the corneal stroma down to Descemet's membrane. It is a partial-thickness cornea transplant procedure that includes the elective transplantation of the corneal stroma and leaves the native Descemet membrane and endothelium in place. It is an effective treatment for any pathology of the anterior cornea including the epithelium, Bowman's layer and stroma. The use of the deep anterior lamellar keratoplasty has demonstrated the reduced rejection rate as this surgical procedure preserves the host endothelium among the patients. The shorter healing time fewer postoperative complications and shorter use of topical steroid treatment was observed among the patients who had undergone deep anterior lamellar keratoplasty.

By Procedure Type, penetrating keratoplasty is Expected to Witness a Significant Growth Over the Forecast Period

The market is classified based on the procedure type as the pre-operative examination, penetrating keratoplasty, and lamellar keratoplasty. Penetrating keratoplasty segment accounts for a significant market share as it is the most common procedure being performed across the globe. According to the Cincinnati Eye Institute (CEI), every year, approximately 45,000 number of penetrating keratoplasty procedures are performed in the United States. Penetrating keratoplasty involves the surgical removal of the central two-thirds of the damaged cornea and insertion of a matching portion of clear, healthy donor tissue. Penetrating keratoplasty is used for the treatment, and management of corneal edema, corneal ulceration, corneal dystrophy, Fuch's dystrophy, keratoconus, and other conditions. Studies have shown that the penetrating keratoplasty grafts can survive 10 years or longer among the patients.

Geographical Analysis

North America region holds the largest market share global Corneal Surgery Market

North America region is dominating the global corneal surgery market accounted for the largest market share in 2021. The United States is expected to hold the largest share in this region owing to the increasing number of people undergoing corneal surgery with the increase in the number of people affected by visual impairment. According to the Centers for Disease Control and Prevention (CDC), around 12 million people have vision impairment including 1 million people were blind in the United States. According to the American Academy of Ophthalmology, approximately 48,229 corneal transplants were in the United States in 2013. More than one million men, women, & children of age-group nine days to 100+ years have restored their vision through corneal surgery in the United States since 1961.

There is an increase in the number of market players developing corneal surgery devices. Several companies are raising the investment & funding for the development of corneal surgery devices. There is growing usage of advanced methods for performing corneal surgery. There are several organizations, associations, and foundations that are raising awareness regarding corneal surgery. For instance, the Cornea Research Foundation of America (CRFA), a non-profit organization is involved in conducting clinical research and education specializing in corneal disease, corneal transplantation and intraocular lens surgery. Moreover, several companies are also launching their surgical vision centres. For instance, in July 2019, Johnson & Johnson had launched the Surgical Vision Experience Center at the Johnson & Johnson Institute in Jacksonville, Florida. This centre would serve as Johnson & Johnson Vision's premier physical training space and laboratory setting for a variety of experiential educational programs offering hands-on, in-depth training for practising ophthalmic surgeons, ophthalmology residents and optometrists. The availability of better healthcare facilities and infrastructure shall stimulate market growth.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period

Asia-Pacific region is estimated to be the fastest-growing region in the global corneal surgery market owing to the increasing prevalence of various chronic diseases such as diabetes, diabetic retinopathy, obesity, and others increase the chances of eye disorders that could lead to corneal blindness. According to the Global Alliance of Eye Bank Association (GAEBA), around 2.8 million people are affected by corneal blindness in Asia. Approximately 6.8 million people have a vision of less than 6/60 in at least one eye due to corneal diseases. Among these people, one million people have bilateral involvement. As per the National Programme for Control of Blindness (NPCB), there were 120,000 corneal blind persons in India in 2013. Every year, there is an addition of 25,000-30,000 new cases of Corneal blindness. Moreover, the National Programme for Control of Blindness and Visual Impairment was launched in India in 1976 as a 100% centrally sponsored scheme to reduce the prevalence of blindness to 0.3% by 2020. The 2016-17 program collected donated eyes for corneal transplantation and achieved 65,135 out of the target of 50,000.

The drastic market growth is expected to observe in the countries such as India, China, Japan, and Australia due to the increase in the number of ophthalmic clinics, hospitals, and other healthcare organizations providing corneal surgery. There is growing awareness regarding the importance of eye donation shall have a positive impact on the market. Several companies are focussing on developing technologically advanced corneal surgery devices. There is growing initiatives by the government for providing low-cost ophthalmic procedures in clinics and hospitals. The improvement in eye care facilities, eye banking framework and cornea trade protocols shall boost the demand for corneal surgery.

Competitive Landscape:

The corneal surgery market studied is a fragmented market with the presence of a large number of market players. Nidek Co. Ltd, Johnson & Johnson, Essilor International S.A., Topcon Corporation, Ziemer Ophthalmic Systems AG, Carl Zeiss Meditec, Bausch & Lomb, Abbott Medical, Alcon Laboratories, Meditec AG, Medical Optics Inc., and Cooper Vision are the major players with significant market share. The major players are adopting several growth strategies, such as product launches, product approvals, mergers, licensing, acquisitions, and collaborations, contributing to the growth of the global corneal surgery market. For instance,

Mergers & Collaborations:

In October 2019, TECLens entered into a collaboration with SERVimed Industrial Spa for the development and FDA approval of a new combination product to treat keratoconus. The new product under development would combine TECLens' CXLens 'on-eye' cross-linking system for corneal remodeling with SERVImed's trans-epithelial RIBOCROSS riboflavin drug formulation.

On 18th July 2022, Carl Zeiss Meditec partnered with Precise Bio to develop and commercialize fabricated corneal tissue for Ophthalmology. Under the agreement, Carl Zeiss Meditec will invest in Precise Bio to develop cornea transplant products.

Product Launch & Approvals:

On 24th May 2021, Haag-Streit UK launched the Eyestar 900 eye analyzer in the UK. The swept-source technology enables precise measurement of the entire eye and topographic assessment of the front and back corneal surface and the anterior chamber, including the lens. In addition to imaging all of these structures, it includes cornea-to-retina biometry of the entire eye.

On 31st July 2019, Johnson & Johnson Vision announced its launch of the Surgical Vision Experience Center at the Johnson & Johnson Institute in Jacksonville, FL. The Surgical Center will serve as its premier physical training space and laboratory setting for various experiential educational programs offering hands-on, in-depth training for practicing ophthalmic surgeons, ophthalmology residents and optometrists.

Acquisition:

On 14th July 2021, Topcon Corporation announced it had acquired VISIA Imaging S.r.l, an ophthalmic device manufacturer. This acquisition enhances Topcon development and boosts the manufacturing capacity of anterior segment devices and software. The segment devices include cameras and optical coherence tomography (OCT).

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Device Type
• 3.2. Market Snippet by Transplantation Type
• 3.3. Market Snippet by Procedures
• 3.4. Market Snippet by End-User
• 3.5. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Vision Impairment
    • 4.1.1.2. Technological Advancements
    • 4.1.1.3. XX
  • 4.1.2. Restraints:
    • 4.1.2.1. Adverse Events with use of Corneal Surgery Devices
    • 4.1.2.2. XX
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiology
• 5.3. Pipeline Analysis
• 5.4. Supply Chain Analysis
• 5.5. Pricing Analysis
• 5.6. Regulatory Analysis
• 5.7. Reimbursement Analysis
• 5.8. Unmet Needs

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Device Type

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type Segment
• 7.3. Market Attractiveness Index, By Device Type Segment
  • 7.3.1. Diagnostic Devices*
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.1.3. Fundus Cameras
    • 7.3.1.4. Keratometers
    • 7.3.1.5. Corneal Topographer
    • 7.3.1.6. Ophthalmic Ultrasound Imaging Systems
    • 7.3.1.7. Others
  • 7.3.2. Corneal Surgery Devices
  • 7.3.3. Vision Care

8. By Transplantation Type

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
• 8.3. Market Attractiveness Index, By Transplantation Type Segment
  • 8.3.1. Deep Anterior Lamellar Keratoplasty*
    • 8.3.1.1. Introduction
    • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3.2. Penetrating Keratoplasty
  • 8.3.3. Synthetic Corneas
    • 8.3.3.1. Boston Keratoprosthesis
    • 8.3.3.2. Alphacor
    • 8.3.3.3. Osteo-Odonto-Keratoprosthesis
  • 8.3.4. Others

9. By Procedures

• 9.1. Introduction
• 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
• 9.3. Market Attractiveness Index, By Procedures Segment
  • 9.3.1. Pre-Operative Examination*
    • 9.3.1.1. Introduction
    • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3.2. Penetrating Keratoplasty
  • 9.3.3. Lamellar Keratoplasty

10. By End-User

• 10.1. Introduction
• 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
• 10.3. Market Attractiveness Index, By End-User Segment
  • 10.3.1. Ophthalmic Clinics*
    • 10.3.1.1. Introduction
    • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 10.3.2. Hospitals
  • 10.3.3. Others

11. By Region

• 11.1. Introduction
• 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
• 11.3. Market Attractiveness Index, By Region
• 11.4. North America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
  • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
  • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
  • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. U.S.
    • 11.4.7.2. Canada
    • 11.4.7.3. Mexico
• 11.5. Europe
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
  • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
  • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
  • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. Germany
    • 11.5.7.2. U.K.
    • 11.5.7.3. France
    • 11.5.7.4. Italy
    • 11.5.7.5. Spain
    • 11.5.7.6. Rest of Europe
• 11.6. South America
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
  • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
  • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
  • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.6.7.1. Brazil
    • 11.6.7.2. Argentina
    • 11.6.7.3. Rest of South America
• 11.7. Asia Pacific
  • 11.7.1. Introduction
  • 11.7.2. Key Region-Specific Dynamics
  • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
  • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
  • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
  • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.7.7.1. China
    • 11.7.7.2. India
    • 11.7.7.3. Japan
    • 11.7.7.4. Australia
    • 11.7.7.5. Rest of Asia Pacific
• 11.8. Middle East and Africa
  • 11.8.1. Introduction
  • 11.8.2. Key Region-Specific Dynamics
  • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
  • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Transplantation Type
  • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedures
  • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Nidek Co. Ltd*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Key Highlights
  • 13.1.4. Financial Overview
• 13.2. Johnson & Johnson
• 13.3. Essilor International S.A.
• 13.4. Topcon Corporation
• 13.5. Ziemer Ophthalmic Systems AG
• 13.6. Haag-Streit
• 13.7. Carl Zeiss Meditec
• 13.8. Bausch & Lomb
• 13.9. Abbott Medical
• 13.10. KeraMED
• 13.11. Alcon Laboratories
• 13.12. Meditec AG
• 13.13. Medical Optics Inc.
• 13.14. Cooper Vision(LIST NOT EXHAUSTIVE)

14. DataM Intelligence

• 14.1. Appendix
• 14.2. About Us and Services
• 14.3. Contact Us